Authors

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.

Elacestrant Outperforms SOC in Terms of PFS in ER+/HER2– mBC

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.

World Cancer Day: Next Generation Sequencing at the Forefront of Precision Medicine

Next generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.

TBI-Free Transplant Works for Younger Patients with B-ALL

Gender-Specific AI Model Advances Understanding of Glioblastoma Progression and Treatment Response

Distinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.

Adaptation in Oncology Practice Opens the Door to Specialization

Demands by patients, market pressures, and changing delivery models have brought to the fore the urgency to address whether subspecialization is necessary and entirely feasible.

Gynecologic Cancer Awareness Month: Progress Makes Cervical Cancer Highly Treatable, Increasingly Preventable

For Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.

How Data Help Physicians Improve Operations and Achieve Health Equity

A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift care from reactive to preventive, easing strain on systems.

Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With Abemaciclib

Dose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.

Exploring Advancements in Higher-Risk MDS

Despite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.

Pegsitacianine Informs Surgery in Peritoneal Carcinomatosis

Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.

Turning the Tide on Opioid Prescribing Practices

In 2017 there was a continued increase in opioid-related deaths in the United States, with more than 60,000 lives lost. Most opioid abusers report that their opioids are acquired with their own prescription or a prescription for someone else obtained illegally. Two recent retrospective studies found that in patients undergoing surgery for early non–small cell lung cancer, perioperative opioid use was associated with decreased OS and increased risk of recurrence.

Curing Versus Managing CLL

Adrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).

Later-Line Management of Metastatic Triple Negative Breast Cancer

Triple-negative breast cancer — defined as tumors that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification— is a heterogenous disease and clinically represents a major unmet need in the field of oncology. TNBC is associated with aggressive tumor biology and higher risk of recurrence and visceral metastasis, including brain metastasis.

Clinical Development of Cyclin-Dependent Kinase Inhibitors in Lung Cancer

This manuscript focuses on the latest clinical developments of newer generation selective CDK inhibitors in lung cancer.

Gene Removal May Pose Future Treatment in Advanced Melanoma

Despite the availability of several new agents in the past 5 years for the treatment of melanoma, patients with advanced melanoma still suffer poor prognoses.